PPC
REGN icon

Park Place Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Park Place Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$2.14K – 866
2024
Q4 		$2.14K Hold
3
– – ﹤0.01% 725
2024
Q3 		$3.15K Hold
3
– – ﹤0.01% 733
2024
Q2 		$3.15K Sell
3
-4
-57% -$3.88K ﹤0.01% 738
2024
Q1 		$6.74K Sell
7
-15
-68% -$14.3K ﹤0.01% 706
2023
Q4 		$19.3K Sell
22
-73
-77% -$60.1K 0.01% 537
2023
Q3 		$78.2K Buy
95
+15
+19% +$11.8K 0.02% 394
2023
Q2 		$57.5K Sell
80
-3
-4% -$2.31K 0.02% 466
2023
Q1 		$68.2K Sell
83
-14
-14% -$10.6K 0.02% 431
2022
Q4 		$70K Buy
+97
New +$71.6K 0.02% 433

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Park Place Capital's REGN Position: Q1 2025 in Review

Park Place Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 3 shares — an estimated $2.14K sold.

Park Place Capital first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $78.2K in Q3 2023. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Park Place Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Park Place Capital sold 3 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $2.14K.
  • Park Place Capital first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Park Place Capital's Regeneron Pharmaceuticals position peaked at $78.2K in Q3 2023.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Park Place Capital's 13F filing for Q1 2025, filed 24 Apr 2025.